Successful presentation by Cereno at ISTH in Melbourne – wins the "Top Poster" award

This post was originally published on this site

Thu, Jul 11, 2019 13:28 CET

Cereno Scientific AB has recently participated in the annual major scientific conference on thrombosis related diseases ISTH in Melbourne, Australia, where interest in Cereno's drug candidate CS1 was great. The company's co-founder Pia Larsson, PhD presented Cereno's abstract “A New Treatment for Thrombosis Prevention?” in the form of a poster that received the award “Top Poster Winner”.

– It is always rewarding to meet the world's leading scientists and companies in the field and present our research to key stakeholders. Winning the prize Top Poster is an acknowledgment that our research is of high international standard and that we are on the right track with our work, says Cereno Scientific's CEO Sten R. Sörensen.

Cereno Scientific received patent approval in Australia for the use of drug candidate CS1 earlier in the spring of 2019.

About ISTH 2019
At ISTH 2019, thousands of the world’s leading experts on thrombosis, hemostasis and vascular biology come together. Through extensive educational sessions, lectures and networking opportunities, the conference promotes the latest scientific advances and applications to improve the development of new treatment principles and thus patient care worldwide.

For further information, please contact: 

Daniel Brodén  – CFO
Tel: +46 768 66 77 87
E-mail: [email protected] 

About Cereno Scientific AB 
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.

Recommended For You


About the Author: Sidney Martin

Sidney Marin Is a researcher and law student at York University (TORONTO). He has worked as the Director of the Graduate Lawyering Program. He worked for American law firms in Moscow, Russia for three years. Hegraduated from Columbia Law School, Columbia School of International and Public Affairs and Harvard College. He research interest is in human rights and health law, with a particular focus on the law and policy of vaccination.